Your AI-Trained Oncology Knowledge Connection!

Michael R. Harrison, MD

home / authors / michael-r-harrison-md

Articles

How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?

Ramiro Jose Madden-Fuentes, MD;Bridget F. Koontz, MD;Michael R. Harrison, MD;Daniel J. George, MD;Brittany Davidson, MD;Brian F. Gilmore, MD;Judd W. Moul, MD;Christopher Mantyh, MD;Andrew C. Peterson, MD

April 15th 2017

Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.

Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train?

Michael R. Harrison, MD;Sundhar Ramalingam, MD

April 15th 2016

Men with high-risk nonmetastatic CRPC should if possible be enrolled in a clinical trial and that patients with low-risk disease can be safely observed.

What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?

Sundhar Ramalingam, MD;Kathryn I. Pollak, PhD;Leah L. Zullig, PhD, MPH;Michael R. Harrison, MD

September 15th 2015

There is ample evidence suggesting that physical activity and exercise can be therapeutic tools for patients with prostate cancer. Patients diagnosed with localized disease should be advised to stay physically active; furthermore, patients who are undergoing radiation therapy and/or treatment with ADT appear to benefit from regular aerobic and resistance exercise to alleviate side effects.

Response to Antiangiogenesis Therapy in a Patient With Advanced Adult-Type Testicular Granulosa Cell Tumor

Michael R. Harrison, MD;Wei Huang, MD;Glenn Liu, MD;Jason Gee, MD

August 18th 2009

We have presented the first case of a patient with metastatic ATGCT with peritoneal carcinomatosis, who responded to treatment with a VEGFR tyrosine kinase inhibitor. Because of the relative paucity of such cases in the literature, no clear treatment strategy exists. For patients with metastatic ATGCT, enrollment in clinical trials testing novel therapies, including angiogenesis inhibitors, is a reasonable option.